Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PVLA
Strong SellSinkerPalvella Therapeutics, Inc. · Healthcare · United States · $2.2B · Avg Vol: $27M/d
COMPANY DESCRIPTION
Palvella Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutics for rare, severe genetic skin diseases. Its lead product candidate, PTX-022, targets epidermolysis bullosa simplex (EBS), a debilitating genetic disorder with high unmet medical need. The company's focus on orphan diseases grants it potential for market exclusivity and accelerated regulatory pathways, positioning it in a specialized, high-barrier-to-entry biopharmaceutical niche.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 28.9M | — |
| EPS | -2.46 | 1.60 | -7.83 | -3.71 | — | -4.86 | -6.37 | -7.50 | — |
| Shares | 11.2M | 11.0M | 11.0M | 12.4M | +10.3% | 14.4M | — | — | — |
| Debt | — | — | 0 | 0.6M | — | — | — | — | — |
| Equity | -23.2M | -3.9M | 62.6M | 28.0M | -55.3% | — | — | — | — |
| Op CF | -14.8M | -13.7M | -10.8M | -25.0M | — | -36.5M | — | — | — |
| Inv CF | — | — | — | — | — | — | — | — | — |
| Fin CF | 9.6M | 5.0M | 87.1M | -0.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PVLA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PVLA | Palvella Therapeutics, Inc.(you) | $2.2B | 16 | Strong Sell |
| ZBIO | Zenas BioPharma, Inc. | $2.0B | 15 | Strong Sell |
| OCUL | Ocular Therapeutix, Inc. | $2.3B | 18 | Strong Sell |
| BHVN | Biohaven Ltd. | $2.3B | 18 | Strong Sell |
| MLYS | Mineralys Therapeutics, Inc. | $2.3B | 14 | Strong Sell |
| RAPP | Rapport Therapeutics, Inc. | $2.3B | 19 | Strong Sell |
| STOK | Stoke Therapeutics, Inc. | $2.0B | 13 | Strong Sell |
| TSHA | Taysha Gene Therapies, Inc. | $1.9B | 14 | Strong Sell |
| KLRA | Kailera Therapeutics, Inc. | $2.1B | 11 | Strong Sell |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.1B | 11 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%